Astec Lifescienc

Has Astec Lifescienc declared dividend?

Astec Lifesciences Ltd has declared a 15% dividend, amounting to ₹1.5 per share, with an ex-date of July 21, 2023. However, the dividend yield is 0%, and total returns over various periods show significant declines in stock price.

Astec Lifesciences Ltd has declared a 15% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 15%<BR>- Amount per share: 1.5<BR>- Ex-date: 21 Jul 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -26.09%, the dividend return was 0%, resulting in a total return of -26.09%.<BR><BR>Over the past year, the price return was -30.47%, the dividend return was 0%, leading to a total return of -30.47%.<BR><BR>In the 2-year period, the price return was -43.16%, with a dividend return of 0.11%, culminating in a total return of -43.05%.<BR><BR>For the 3-year period, the price return was -55.72%, the dividend return was 0.17%, resulting in a total return of -55.55%.<BR><BR>In the 4-year period, the price return was -42.55%, with a dividend return of 0.33%, leading to a total return of -42.22%.<BR><BR>Over the last 5 years, the price return was 8.85%, the dividend return was 0.74%, resulting in a total return of 9.59%.<BR><BR>Overall, while Astec Lifesciences Ltd has declared a dividend, the total returns over various periods indicate significant declines in price, with only modest positive returns in the longer term. The dividend yield remains at 0%, suggesting limited income generation from dividends relative to the stock price.

Who are the peers of the Astec Lifescienc?

Astec Lifescienc's peers include P I Industries, UPL, Bayer CropSci., and others. In terms of management risk, Astec Lifescienc is rated below average, with a 1-year return of -35.47%, the lowest among its peers.

Peers: The peers of Astec Lifescienc are P I Industries, UPL, Bayer CropSci., Sumitomo Chemi., Dhanuka Agritech, Heranba Inds, Dharmaj Crop, Shivalik Rasayan, and Best Agrolife.<BR><BR>Quality Snapshot: Excellent management risk is observed at Bayer CropSci., Dhanuka Agritech, and P I Industries, while Good management risk is found at Sumitomo Chemi., Best Agrolife, and Heranba Inds. Average management risk is present at UPL, Dharmaj Crop, and the rest. Below Average management risk is noted at Astec Lifescienc and Shivalik Rasayan. In terms of Growth, Excellent growth is seen at P I Industries, while Average growth is found at Dharmaj Crop and the rest. Below Average growth is noted at UPL, Bayer CropSci., Sumitomo Chemi., Dhanuka Agritech, Heranba Inds, Astec Lifescienc, Shivalik Rasayan, and Best Agrolife. Capital Structure ratings show Excellent at Bayer CropSci., Sumitomo Chemi., and Dhanuka Agritech, while Good is seen at Heranba Inds and Dharmaj Crop. Average capital structure is noted at Astec Lifescienc and Best Agrolife, with Below Average at UPL and Shivalik Rasayan.<BR><BR>Return Snapshot: Dhanuka Agritech has the highest 1-year return at 32.65%, while Astec Lifescienc has the lowest at -35.47%, indicating a significant negative performance compared to its peers. Additionally, peers with negative six-month returns include Astec Lifescienc, Heranba Inds, and Best Agrolife.

Who are in the management team of Astec Lifescienc?

As of March 2023, the management team of Astec Lifescienc includes Ashok V Hiremath (Director), N B Godrej (Chairman), Balram Yadav (Director), Anurag Roy (Whole Time Director & CEO), and several independent directors, among others. The team consists of a mix of directors and key executive roles.

As of March 2023, the management team of Astec Lifescienc includes the following individuals:<BR><BR>1. Ashok V Hiremath - Director<BR>2. N B Godrej - Chairman (Non-Executive)<BR>3. Balram Yadav - Director<BR>4. Vijay Kashinath Khot - Independent Director<BR>5. Brahma Nand Vyas - Independent Director<BR>6. Tejashree Pradhan - Company Secretary & Compliance Officer<BR>7. Govindan Ramakrishna Rishinaradamangalam - Independent Director<BR>8. Dhekne Vasant Nandkumar - Independent Director<BR>9. Anjali Rajesh Gupta - Independent Director<BR>10. Anurag Roy - Whole Time Director & CEO<BR>11. Burjis Godrej - Director<BR><BR>This team encompasses a mix of directors, independent directors, and key executive roles.

What does Astec Lifescienc do?

Astec Lifesciences Ltd is a small-cap company that produces agrochemicals and pharmaceutical intermediates, reporting net sales of 1,195 Cr and a net loss of 161 Cr for March 2025. The company has a market cap of INR 2,067 Cr and a debt-to-equity ratio of 2.35.

Overview:<BR>Astec Lifesciences Ltd is a producer of agrochemicals and pharmaceutical intermediates, operating within the Pesticides & Agrochemicals industry and classified as a Small Cap company.<BR><BR>History:<BR>The company was incorporated in an unspecified year and has undergone no status changes. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,195 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: -161 Cr (Quarterly Results - Mar 2025)<BR>- Market cap: INR 2,067 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A (Loss Making)<BR>- Industry P/E: 40<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 2.35<BR>- Return on Equity: -57.40%<BR>- Price to Book: 8.80<BR><BR>Contact Details:<BR>Address: GodrejOne 3rd Fl Pirojshanagar, Vikhroli (E) Eastern Exp Highw Mumbai Maharashtra : 400079<BR>Tel: 91-22-25188010<BR>Email: astecinfo@godrejastec.com<BR>Website: http://www.astecls.com

Who are the top shareholders of the Astec Lifescienc?

The top shareholder of Astec Lifescienc is Godrej Agrovet Limited, with a 64.75% stake. Other shareholders include individual investors (19.62%), mutual funds (3.96%), and foreign institutional investors (0.25%), with Nippon Life India Trustee Ltd being the largest public shareholder at 2.35%.

The top shareholders of Astec Lifescienc include Godrej Agrovet Limited, which holds the largest stake at 64.75%. The company also has a diverse range of other shareholders, including individual investors who collectively own 19.62% of the shares. Additionally, mutual funds hold 3.96% across three schemes, while foreign institutional investors (FIIs) have a smaller stake of 0.25% through eight different entities. The highest public shareholder is Nippon Life India Trustee Ltd, which manages the Nippon India Small Cap Fund, holding 2.35%.

How big is Astec Lifescienc?

As of 24th July, Astec Lifesciences Ltd has a market capitalization of 2,028.00 Cr and reported net sales of 381.31 Cr with a net loss of 134.75 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Astec Lifesciences Ltd has a market capitalization of 2,028.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 381.31 Cr, while the sum of Net Profit for the same period reflects a loss of 134.75 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 234.75 Cr and Total Assets valued at 881.42 Cr.

How has been the historical performance of Astec Lifescienc?

Astec Lifescienc has experienced a significant decline in net sales and profitability, with losses increasing from a profit of 89.88 crore in March 2022 to a loss of 134.71 crore in March 2025, alongside a decrease in total assets and negative cash flow from operations.

Answer:<BR>The historical performance of Astec Lifescienc shows a declining trend in net sales and profitability over the past few years, culminating in significant losses in the most recent fiscal year.<BR><BR>Breakdown:<BR>Astec Lifescienc's net sales have decreased from 676.57 crore in March 2022 to 381.30 crore in March 2025, reflecting a downward trend in revenue generation. The total operating income followed a similar pattern, dropping from 676.57 crore in March 2022 to 381.30 crore in March 2025. The company's total expenditure, excluding depreciation, peaked at 551.91 crore in March 2023 but slightly decreased to 447.51 crore in March 2025. This resulted in an operating profit (PBDIT) that fell from 164.55 crore in March 2022 to a loss of 60.58 crore in March 2025. The profit before tax also turned negative, going from a profit of 121.13 crore in March 2022 to a loss of 140.99 crore in March 2025. Consequently, the profit after tax showed a similar decline, moving from a profit of 89.88 crore in March 2022 to a loss of 134.71 crore in March 2025. The company's total assets decreased from 979.41 crore in March 2023 to 881.42 crore in March 2025, while total liabilities also decreased from 974.93 crore to 881.42 crore during the same period. Cash flow from operating activities turned negative in March 2025, indicating challenges in generating cash from core operations. Overall, Astec Lifescienc has faced significant financial difficulties, leading to substantial losses and a decline in key financial metrics over the past few years.

Is Astec Lifescienc technically bullish or bearish?

As of November 21, 2025, the technical trend for Astec Lifesciences is mildly bearish with mixed signals across various indicators, suggesting caution in the current market environment.

As of 21 November 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish with weak strength. Key indicators include a bearish MACD on the weekly timeframe, a mildly bullish MACD on the monthly, and a mildly bearish moving average on the daily. The RSI is bearish on the weekly and shows no signal on the monthly. While the Bollinger Bands indicate bullishness on the weekly, they are mildly bearish on the monthly. The KST remains bearish across both timeframes, and Dow Theory shows mildly bullish on the weekly but mildly bearish on the monthly. Overall, the mixed signals suggest caution in the current market environment for Astec Lifescienc.

When is the next results date for Astec Lifesciences Ltd?

Astec Lifesciences Ltd will announce its results on January 30, 2026.

Astec Lifesciences Ltd is scheduled to declare its results on January 30, 2026.

Are Astec Lifesciences Ltd latest results good or bad?

Astec Lifesciences Ltd's latest results show strong revenue growth of 27.18% quarter-on-quarter and 32.70% year-on-year, but the company reported a net loss of ₹7.76 crores, indicating ongoing profitability challenges. While there are positive signs, investors should be cautious due to the uncertain path to sustainable profitability.

Astec Lifesciences Ltd's latest results present a mixed picture. On one hand, the company reported a significant quarter-on-quarter revenue growth of 27.18%, reaching ₹158.62 crores, which is the highest quarterly revenue in recent periods. Year-on-year, revenue also increased by 32.70%. This indicates a positive trend in sales performance.<BR><BR>However, despite this revenue growth, the company continues to face challenges with profitability. In Q4 FY26, Astec reported a net loss of ₹7.76 crores, although this was an improvement of 50.57% compared to the previous quarter's loss of ₹15.70 crores. The operating margin, while improving to 5.77% from 3.20% in the previous quarter, remains significantly lower than historical levels, which were above 20%.<BR><BR>Overall, while there are signs of recovery in terms of revenue and operational performance, the ongoing losses and structural issues within the company, particularly in the context of a challenging agrochemical sector, suggest that the latest results are not entirely positive. Investors should remain cautious, as the path to sustainable profitability is still uncertain.

Should I buy, sell or hold Astec Lifesciences Ltd?

Why is Astec Lifesciences Ltd falling/rising?

As of 05-May, Astec Lifesciences Ltd's stock is declining, currently priced at Rs 673.35, down 5.05%. The stock has underperformed its sector and benchmarks, showing weak long-term fundamentals and significant financial strain.

As of 05-May, Astec Lifesciences Ltd's stock price is falling, currently at Rs 673.35, which reflects a decrease of Rs 35.8 or 5.05%. This decline is evident in the stock's performance today, where it underperformed its sector by 4.74% and reached an intraday low of Rs 665.25, marking a drop of 6.19%. <BR><BR>The stock has shown a negative trend over the past week, with a decrease of 7.43%, while the benchmark Sensex has increased by 0.17%. Additionally, the stock's year-to-date performance is down by 4.52%, contrasting with a more significant decline of 9.63% in the Sensex. Over the last three years, Astec Lifesciences Ltd has consistently underperformed against the benchmark, with a staggering 50.63% drop compared to a 26.15% rise in the Sensex.<BR><BR>Investor participation has also been declining, as indicated by a 16.32% drop in delivery volume compared to the five-day average. Although the company reported positive results for the quarter ending March 26, including the highest net sales at Rs 158.62 crore, the long-term fundamentals remain weak. The company has a high Debt to EBITDA ratio of 99.10 times and has recorded a negative EBITDA of Rs -4.53 crore, indicating significant financial strain.<BR><BR>Overall, the combination of poor long-term growth prospects, negative profitability indicators, and consistent underperformance against benchmarks contributes to the stock's current decline.

Which are the latest news on Astec Lifescienc?